The Gould Group
The Gould group aims to advance human IgE biology, involving IgE itself, its receptors FceRI and CD23 and the counter-receptors of CD23, complement receptor 2 (CR2 or CD21) and complement receptors 3 and 4 (CD11CD18a and CD11CD18b), which together form the "Human IgE Network". We analyse high resolution protein structures, interactions between these molecules and the physiological functions and regulation of IgE in relation to allergic disease and cancer.
Increasingly we are participating in translational research to exploit our knowledge in therapy. We are currently engaged in clinical trials on anti-IgE in non-atopic asthma and IgE immunotherapy of cancer
This research benefits from several collaborations within the MRC-Asthma UK Centre in Molecular Mechanisms of Asthma (Prof. Brian Sutton*, Prof. Jim McDonnell* and Dr. Andrew Beavil* in the Randall; Prof. Christopher Corrigan*, Prof. Gideon Lack*, Dr. Alexandra Santos*, and Dr. David Fear* in the Division of Allergy, Asthma and Lung Biology; and Prof. Stephen Durham* and Prof. Sebastian Johnston* at Imperial College), and with other groups at Guy's Hospital (Dr. Sophia Karagiannis, Dr. James Spicer and Prof. Frank Nestle), and with colleagues around the world (Dr. Gary Felsenfeld, USA; Dr. Toshiaki Kawakami (USA), Dr. Stephen Kleinstein (USA), Prof. Tse Wen Chang (Taiwan).
* in the MRC and Asthma UK Centre in Allergic Mechanisms of Asthma
Sources of funding for the group